We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $11.5B
1-Year Est. Return 168.77%
This Fund
S&P 500
This Quarter Est. Return
+13.75%
1 Year Est. Return
+168.77%
3 Year Est. Return
+596.08%
5 Year Est. Return
+846.46%
10 Year Est. Return
+54,223.74%
AUM
$1.01B
AUM Growth
+$76.5M
Cap. Flow
+$73.9M
Cap. Flow %
7.34%
Top 10 Hldgs %
62.46%
Holding
63
New
12
Increased
4
Reduced
12
Closed
6

Top Buys

Rank Stock Value
1
ABUS icon
Arbutus Biopharma
ABUS
+$55.6M
2
DVAX
Dynavax Technologies
DVAX
+$49.8M
3
ACHN
Achillion Pharmaceuticals
ACHN
+$18.8M
4
ASND icon
Ascendis Pharma A/S
ASND
+$18.6M
5
OMER icon
Omeros
OMER
+$17.1M

Top Sells

Rank Stock Value
1
BLUE
bluebird bio
BLUE
+$31.1M
2
RGLS
Regulus Therapeutics
RGLS
+$20.9M
3
FWP
Forward Pharma A/S American Depositary Shares
FWP
+$20.2M
4
NVAX icon
Novavax
NVAX
+$14.7M
5
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$13.9M

Sector Composition

Rank Sector Weight
1 Healthcare 81.3%
2 Miscellaneous 18.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OREX
26
DELISTED
Orexigen Therapeutics, Inc.
OREX
$9.29M 0.92%
+118,623
New +$7.36M
TENX icon
27
Tenax Therapeutics
TENX
$68.5M
$8.71M 0.86%
83
– –
TRVN
28
DELISTED
Trevena, Inc.
TRVN
$8.64M 0.86%
2,121
-2,638
-55% -$9.68M
SCMP
29
DELISTED
Sucampo Pharmaceuticals, Inc.
SCMP
$7M 0.7%
+450,000
New +$6.98M
AKBA icon
30
Akebia Therapeutics
AKBA
$250M
$6.64M 0.66%
597,363
– –
FRTX
31
DELISTED
Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
$6.64M 0.66%
2,230
+261
+13% +$835K
AUPH icon
32
Aurinia Pharmaceuticals
AUPH
$2.15B
$6.56M 0.65%
1,504,776
-969,300
-39% -$3.84M
SCYX icon
33
SCYNEXIS
SCYX
$43.7M
$6.55M 0.65%
9,864
-636
-6% -$522K
CYTO
34
DELISTED
Altamira Therapeutics Ltd
CYTO
$5.03M 0.5%
12
– –
ARAV
35
DELISTED
Aravive, Inc. Common Stock
ARAV
$4.25M 0.42%
38,545
– –
CRDF icon
36
Cardiff Oncology
CRDF
$104M
$4.05M 0.4%
+8,253
New +$3.52M
VXRT
37
DELISTED
Vaxart
VXRT
$3.23M 0.32%
127,623
+2,280
+2% +$62.8K
RMTI icon
38
Rockwell Medical
RMTI
$31.6M
$2.73M 0.27%
2,275
-4,145
-65% -$4.85M
TTOO
39
DELISTED
T2 Biosystems, Inc
TTOO
$2.14M 0.21%
28
– –
OCRX
40
DELISTED
Ocera Therapeutics, Inc.
OCRX
$1.97M 0.2%
417,476
– –
CASC
41
DELISTED
Cascadian Therapeutics, Inc.
CASC
$1.9M 0.19%
+194,294
New +$1.91M
AGIO icon
42
Agios Pharmaceuticals
AGIO
$1.96B
$1.66M 0.16%
17,600
– –
LUMO
43
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$1.64M 0.16%
3,333
– –
PTCT icon
44
PTC Therapeutics
PTCT
$5.48B
$1.57M 0.16%
25,800
– –
MACK
45
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$1.38M 0.14%
14,794
– –
RGEN icon
46
Repligen
RGEN
$9.86B
$1.37M 0.14%
45,000
– –
TSRO
47
DELISTED
TESARO, Inc.
TSRO
$1.35M 0.13%
+23,500
New +$1.11M
ALKS icon
48
Alkermes
ALKS
$7.72B
$1.17M 0.12%
19,200
– –
WGBS
49
DELISTED
WaferGen Bio-systems, Inc.
WGBS
$1.16M 0.11%
51,080
-60,920
-54% -$1.21M
REGN icon
50
Regeneron Pharmaceuticals
REGN
$79.7B
$1.11M 0.11%
2,450
– –
1
2
3

Similar funds

AAIS
ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $11.5B AUM 18.82% 1-Year Est. Return
CC
Centiva Capital New York $11.5B AUM 31.97% 1-Year Est. Return
AI
Axiom Investors Greenwich, Connecticut $11.6B AUM 69.67% 1-Year Est. Return
BMSSC
B. Metzler seel. Sohn & Co Frankfurt, Germany $11.6B AUM 34.29% 1-Year Est. Return
HTC
Haverford Trust Company Radnor, Pennsylvania $11.6B AUM 18.97% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

RA Capital Management's Q1 2015 Portfolio in Review

As of Q1 2015, RA Capital Management held 63 positions worth $1.01B, up 8.2% from $930M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

RA Capital Management deployed $73.9M of net new capital in Q1 2015, opening 12 new positions and adding to 4 existing holdings. Its largest new stake was Arbutus Biopharma: 2,714,800 shares worth $47.4M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, up from 73% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was bluebird bio, an estimated $31.1M trimmed.

  • RA Capital Management's largest Q1 2015 buy was Arbutus Biopharma: 2,714,800 shares worth $47.4M.
  • RA Capital Management added most to Achillion Pharmaceuticals in Q1 2015, an estimated $18.8M increase.
  • RA Capital Management's biggest Q1 2015 reduction was bluebird bio, cutting an estimated $31.1M.
  • RA Capital Management fully exited Forward Pharma A/S American Depositary Shares in Q1 2015, selling an estimated $20.2M.
  • RA Capital Management's ten largest holdings make up 62% of its $1.01B portfolio in Q1 2015.
  • RA Capital Management opened 12 new positions and closed 6 in Q1 2015.
  • RA Capital Management's portfolio value rose 8.2% quarter-over-quarter to $1.01B.

Based on RA Capital Management's 13F filing for Q1 2015, filed 15 May 2015.